Chart of the Week: Celgene Poised to Dominate Personalized Medicine?

In our Charts of the Week over the last several weeks we have been analyzing the use of unique biomarkers by pharmaceutical companies.  We are extending that analysis today with a look at the biomarker discovery activity of pharma companies as compared with the number...

Light Hand Regulating Laboratory Developed Tests (LDTs)

Hello and welcome to the second half of the first Amplion company blog where I mapped out why our team is dedicated to seeing the promise of personalized medicine fully realized. So now I’m going to cover why we believe that 510(k)-style regulation of LDTs...